Rock Creek Pharmaceuticals Inc. (fka RCPIQ)

[Buddhahead]

Catabasis Pharmaceuticals to Present at Muscular Dystrophy Association Scientific Conference in Business Wire, March 10, 2015

Excerpts:
"Catabasis Pharmaceuticals, Inc., a clinical stage drug development company built on a pathway pharmacology technology platform, today announced that CAT-1004 will be featured in an oral presentation and a poster presentation at the upcoming Muscular Dystrophy Association Scientific Conference. The Muscular Dystrophy Association Scientific Conference will be held March 11-14, 2015, in Washington, DC."

"CAT-1004 is a new chemical entity that inhibits activated NF-kB, a protein that coordinates cellular response to muscular damage, stress and inflammation and plays an important role in muscle health. In skeletal muscle, activated NF-kB drives muscle degeneration and suppresses muscle regeneration. In animal models of DMD, CAT-1004 inhibited activated NF-kB, reduced muscle inflammation and degeneration and increased muscle regeneration. In Phase 1 clinical trials, CAT-1004 inhibited NF-kB and was well tolerated with no observed safety concerns. Catabasis Pharmaceuticals plans to initiate a Phase 1/2 clinical trial of CAT-1004 for the treatment of DMD in the first half of 2015."

Article at:
http://www.businesswire.com/news/home/20150310005110/en/Catabasis-Pharmaceuticals-Present-Muscular-Dystrophy-Association-Scientific#.VP93EfmUcrV